Tagged with GE

Association of Producers of generic medicines in Romania (APMGR) APMGR is obviously a rather young association that has only really been active since about a year now. Can you first comment on the timing that the Association was called into life? The timing has been quite good, as the generics industry is currently experiencing a strong momentum. Every country,…

Genzyme Chile Genzyme was first established in Chile in 2004 but only opened its sales office in 2008, what was the rationale for the opening of the office at this time considering that you had been present in neighbouring countries 10 years before? The Chilean market is a very difficult one. We…

Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…

Pró Genéricos When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote it.” At that time, generics penetration was around 10.5% – now it’s around 20%. Does this reflect some fundamental change…

Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…

Cegedim Poland Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of Pharmaceutical Executive? On the one hand the pressures and incentives influencing the main stakeholders are the same as elsewhere. But…

Cegedim Dentrite Italy Ten years of experience in the Dendrite group enabled you to cover a number of international positions, before its acquisition by Cegedim in May 2007. How has the integration progressed at the time, and what has this strategic acquisition meant for Dendrite in Italy? Entering the Italian team coming from…

Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…

Celgene Hungary The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies to be adjusting their strategies in this market? The government has a large majority in the parliament since 2 years,…

Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…

Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…

WestHolland Foreign Investment Agency (WFIA) WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the Life Sciences sector. What drives the agency to place so much effort on attracting investments in Life Sciences in the…